Scarica l'app Stockscreener
9.49
5.10%
-0.51
Dopo l'orario di chiusura:
9.47
-0.02
-0.21%
Precedente Chiudi:
$10.00
Aprire:
$10.02
Volume 24 ore:
275.99K
Relative Volume:
1.53
Capitalizzazione di mercato:
$346.66M
Reddito:
-
Utile/perdita netta:
$-35.46M
Rapporto P/E:
-22.50
EPS:
-0.4218
Flusso di cassa netto:
$-34.00M
1 W Prestazione:
-16.75%
1M Prestazione:
-14.04%
6M Prestazione:
+144.59%
1 anno Prestazione:
-33.26%
Intervallo 1D:
$9.41
$10.07
Intervallo di 1 settimana:
$9.41
$11.73
Portata 52W:
$3.35
$14.90
Contineum Therapeutics Inc Stock (CTNM) Company Profile
Nome
Contineum Therapeutics Inc
Settore
Industria
Telefono
(858) 333-5280
Indirizzo
3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO
Confronta CTNM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CTNM
Contineum Therapeutics Inc
|
9.49 | 365.29M | 0 | -35.46M | -34.00M | -0.4218 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Contineum Therapeutics Inc Stock (CTNM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-13 | Iniziato | Leerink Partners | Outperform |
| 2025-09-25 | Iniziato | Leerink Partners | Outperform |
| 2025-06-20 | Iniziato | William Blair | Outperform |
| 2024-10-22 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-30 | Iniziato | Morgan Stanley | Overweight |
| 2024-04-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-04-30 | Iniziato | Stifel | Buy |
Mostra tutto
Contineum Therapeutics Inc Borsa (CTNM) Ultime notizie
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Contineum Therapeutics, Inc. (CTNM) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Wall Street Analysts See a 91.49% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High? - Finviz
Lorrain, Contineum Therapeutics CSO, sells $51k in stock - Investing.com India
Lorrain, Contineum Therapeutics CSO, sells $51k in stock By Investing.com - Investing.com Australia
Contineum Therapeutics announces proposed $75M public offering - MSN
Contineum Therapeutics Submits Phase 2 Trial for PIPE-791 - MSN
Contineum Therapeutics Reports Increased R&D Investment Amid Losses - MSN
Contineum Therapeutics, Inc.(NasdaqGS: CTNM) added to NASDAQ Biotechnology Index - marketscreener.com
Aug Sentiment: Why Contineum Therapeutics Inc. stock is seen as undervaluedInflation Watch & Reliable Intraday Trade Alerts - Улправда
Contineum Therapeutics (NASDAQ:CTNM) Raised to Hold at Wall Street Zen - MarketBeat
Why analysts remain bullish on Contineum Therapeutics Inc. stockMarket Movers & Expert Approved Trade Ideas - Улправда
Why retail investors favor Contineum Therapeutics Inc. stockJuly 2025 Summary & Daily Chart Pattern Signals - Улправда
Why Contineum Therapeutics Inc. stock attracts high net worth investorsWeekly Trend Report & Free Long-Term Investment Growth Plans - Улправда
How risky is Contineum Therapeutics Inc. stock now2025 Trading Volume Trends & Low Risk Entry Point Tips - Улправда
Why Contineum Therapeutics Inc. stock is seen as undervaluedWeekly Profit Recap & Free Technical Pattern Based Buy Signals - Улправда
What risks investors should watch in Contineum Therapeutics Inc. stockOptions Play & Weekly Setup with ROI Potential - Улправда
Published on: 2025-12-19 19:15:06 - Улправда
Why Contineum Therapeutics Inc. stock remains undervaluedEntry Point & Smart Money Movement Alerts - DonanımHaber
What sentiment indicators say about Contineum Therapeutics Inc. stockJuly 2025 Sector Moves & AI Based Trade Execution Alerts - Улправда
Aug Breakouts: Why Contineum Therapeutics Inc. stock is seen as undervalued2025 Earnings Impact & Capital Efficient Trading Techniques - Улправда
Published on: 2025-12-19 11:46:29 - Улправда
Can Contineum Therapeutics Inc. stock deliver strong Q4 earnings2025 Geopolitical Influence & Safe Entry Point Identification - DonanımHaber
Contineum Therapeutics stock drops as company prices upsized $90 million offering - MSN
Contineum Therapeutics Earnings Notes - Trefis
EBITDA per share of Contineum Therapeutics, Inc. – NASDAQ:CTNM - TradingView — Track All Markets
Great Week for Contineum Therapeutics, Inc. (NASDAQ:CTNM) Institutional Investors After Losing 5.3% Over the Previous Year - 富途牛牛
Contineum Therapeutics (NASDAQ:CTNM) Stock Rating Lowered by Wall Street Zen - MarketBeat
Contineum Therapeutics Inc trading resumes - MSN
Contineum price target lowered to $22 from $25 at RBC Capital - MSN
Contineum Therapeutics Prices Upsized $90 Million Class A Share Offering - marketscreener.com
Contineum prices upsized public offering of common stock at $12.25 per share - Investing.com Nigeria
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Contineum prices upsized public offering of common stock at $12.25 per share By Investing.com - Investing.com South Africa
Contineum Therapeutics prices upsized $90 million public offering at $12.25 per share - marketscreener.com
Contineum Therapeutics (NASDAQ: CTNM) sets price for upsized $90.0M offering - Stock Titan
Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering - Business Wire
Contineum Therapeutics launches $75 million public offering of stock By Investing.com - Investing.com Nigeria
Contineum Therapeutics launches $75 million public offering of stock - Investing.com
Contineum Therapeutics falls on planned $75 million share sale - TradingView — Track All Markets
Contineum Therapeutics Announces Proposed $75.0 Million Public Offering - Business Wire
ETFs Investing in Contineum Therapeutics, Inc. Stocks - TradingView — Track All Markets
Contineum Therapeutics, Inc. (NASDAQ:CTNM) institutional owners may be pleased with recent gains after 16% loss over the past year - simplywall.st
Saturn V Capital Management LP Has $1.27 Million Stock Holdings in Contineum Therapeutics, Inc. $CTNM - MarketBeat
Will Contineum Therapeutics Inc. stock rally after Fed decisionsWeekly Profit Recap & Daily Oversold Stock Bounce Ideas - Newser
Contineum Therapeutics, Inc. $CTNM Shares Purchased by Franklin Resources Inc. - MarketBeat
Contineum Therapeutics Inc Azioni (CTNM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):